← Back to patent-cliff list
Tofacitinib citrate (CAGE Bio)
Tier C — Watch / tradeTofacitinib citrate (CAGE Bio)
CAGE Bio Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：JAK1, JAK2, JAK3
Indications (approved)：Alopecia areata, Atopic dermatitis
Regional status
US
Phase II
2024-12-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tofacitinib citrate (CAGE Bio)?
Approved indications include: Alopecia areata, Atopic dermatitis.
When does the Tofacitinib citrate (CAGE Bio) patent expire?
No public expiry year is available for Tofacitinib citrate (CAGE Bio) yet; this page updates once verified.
How do I get a quote for Tofacitinib citrate (CAGE Bio) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03